Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diagnostic Efficacy of GPC3 Targeted PET Imaging for Hepatocellular Carcinoma
NCT07352345Phase 1Not yet recruiting
- Start
- Jan 2026
- Primary completion
- Jun 2027
- Modality
- scFv Fragments
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-XH06 in hepatocellular carcinoma (HCC). Primary endpoint: Standardized Uptake Values at 1 year. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
68Ga-XH06
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07352345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07352345.